lundi 18 juin 2018

Onco Actu du 18 juin 2018

3.3 Prévention - Vaccins

The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010–2016 [Journal of Infectious Diseases]

HPV vaccine has almost wiped out infections in young women, figures show [The Telegraph]

HPV vaccine cuts cancer-causing infection [BBC News]

4.1 Dép., diag. & prono. - Prostate

Prostate Biopsy Complications Deter Patients From Re-Biopsy [Prostate Cancer Advisor]

4.2 Dép., diag. & prono. - Génome

Breast cancer researcher warns against online genetic tests [Imperial College]

Are Genetic Testing Sites the New Social Networks? [NY Times]

5.1 Traitements - Pré-clinique

Cancer researchers target the dormant cells that seed tumours [Nature]

5.12.6 Immunothérapies - AMM

Bristol-Myers’ Opdivo ushers in a new era as the first I-O therapy approved in China [FiercePharma]

Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK [EndPoints]

China National Drug Administration Approves Country’s First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC) [BMS]

5.4 Traitements - Economie

NICE dogs Roche's Perjeta again, this time in postsurgery breast cancer patients [FiercePharma]

5.9.3 EHA

Despite FDA hold, Epizyme’s tazemetostat posts positive interim data [FierceBiotech]

Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Association (EHA) [Epizyme]

Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma [BMS]

Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer [Novartis]

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL [Novartis]

Winners and losers at #EHA18: Shares mostly slide as data from a range of prominent biotechs fail to wow investors [EndPoints]

6.10 Politiques

‘Our NHS is there for us, now it’s time to stand with them’ [Cancer Research UK]

6.4 Médico-éco

Breast cancer patients are being denied 'life-changing' reconstructive surgery, research shows [The Telegraph]

Hundreds of breast cancer patients 'denied reconstruction' [BBC News]

6.7.1 IA/bioinformatique

Microsoft’s purchase of GitHub leaves some scientists uneasy [Nature]

6.9 Controverses

Theranos founder Elizabeth Holmes indicted for alleged fraud, out as CEO [STAT]